vilaprisan: Clinical Trials

7 trials of vilaprisan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 terminated. 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 17Completed 6, Terminated 1

Follow vilaprisan: new trials by email Literature Review of vilaprisan trials Research Report on vilaprisan

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetics and Safety of Vilaprisan in Renal Impairment
Vilaprisan (BAY1002670) - Uterine Fibroids, Endometriosis
Phase 1CompletedBayer262018-02-022019-12-03
Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned
Vilaprisan, BAY1002670, Ulipristal - Leiomyoma
Phase 1TerminatedBayer102017-11-162021-01-06
Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)
Vilaprisan (BAY 1002670), Vilaprisan Placebo, Microgynon - Clinical Trial ,Phase I
Phase 1CompletedBayer712017-07-172019-02-28
Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)
Vilaprisan (BAY1002670) - Leiomyoma
Phase 1CompletedBayer362017-03-282017-08-18
Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan
Vilaprisan (BAY1002670), [14C] Vilaprisan, Itraconazole(ITZ) - Clinical Trial, Phase I
Phase 1CompletedBayer142015-07-012016-03-02
Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan
Vilaprisan (BAY1002670) - Clinical Trial, Phase I
Phase 1CompletedBayer702014-10-012016-03-16
Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670
BAY1002670, Placebo - Leiomyoma
Phase 1CompletedBayer732011-11-012014-04-21

Conditions studied

Leiomyoma (4)  ·  Endometriosis (1)

Sponsors

Bayer (7)

Countries

Germany (4)  ·  United Kingdom (3)  ·  Belgium (1)  ·  United States (1)

Results publications

PMID 27288475, PMID 29330782

NIH funding

2014 (2), 2015 (1), 2016 (1), 2017 (1)